ISO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ISO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
IsoPlexis's change in receivables for the quarter that ended in Dec. 2022 was $-0.23 Mil. It means IsoPlexis's Accounts Receivable increased by $0.23 Mil from Sep. 2022 to Dec. 2022 .
IsoPlexis's change in receivables for the fiscal year that ended in Dec. 2022 was $-0.70 Mil. It means IsoPlexis's Accounts Receivable increased by $0.70 Mil from Dec. 2021 to Dec. 2022 .
IsoPlexis's Accounts Receivable for the quarter that ended in Dec. 2022 was $4.50 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. IsoPlexis's Days Sales Outstanding for the three months ended in Dec. 2022 was 122.23.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. IsoPlexis's liquidation value for the three months ended in Dec. 2022 was $-13.20 Mil.
The historical data trend for IsoPlexis's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IsoPlexis Annual Data | |||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | |||||
Change In Receivables | -0.72 | -0.08 | -1.18 | -0.70 |
IsoPlexis Quarterly Data | |||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | |
Change In Receivables | Get a 7-Day Free Trial | -0.61 | 0.16 | 0.45 | -1.09 | -0.23 |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IsoPlexis (NAS:ISO) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
IsoPlexis's Days Sales Outstanding for the quarter that ended in Dec. 2022 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 4.502 | / | 3.361 | * | 91 |
= | 122.23 |
2. In Ben Graham's calculation of liquidation value, IsoPlexis's accounts receivable are only considered to be worth 75% of book value:
IsoPlexis's liquidation value for the quarter that ended in Dec. 2022 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 37.465 | - | 67.801 | + | 0.75 * 4.502 | + | 0.5 * 27.516 |
= | -13.20 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of IsoPlexis's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Nachum Shamir | director | 12212 TECHNOLOGY BLVD, AUSTIN TX 78727 |
John Strahley | officer: Chief Financial Officer | 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405 |
Sean Mackay | director, officer: Chief Executive Officer | 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405 |
Rew Richard W. Ii | officer: SVP, GC & Secretary | 7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735 |
James R Heath | director | C/O ISOPLEXIS, 35 NE INDUSTRIAL RD, BRANFORD CT 06405 |
Michael Egholm | director | 1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110 |
Siddhartha Kadia | director | 7475 LUSK BOULEVARD, SAN DIEGO CA 92121 |
Jason W. Myers | director | C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301 |
John G. Conley | director | 396 GREAT MEADOWS RD, CONCORD MA 01742-1803 |
Gregory P. Ho | director, 10 percent owner | C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022 |
Peter Siesel | officer: Chief Commercial Officer | 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405 |
Jing Zhou | officer: Chief Scientific Officer | 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405 |
Rajesh T. Khakhar | officer: VP, Finance | 35 NORTH INDUSTRIAL ROAD, BRANFORD CT 06405 |
Northpond Capital Gp, Llc | 10 percent owner | 4 BRATTLE STREET, FLOOR 3, CAMBRIDGE MA 02138 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-30-2022
By GuruFocusNews GuruFocusNews • 04-08-2022
By Value_Insider Value_Insider • 11-09-2022
By PurpleRose PurpleRose • 08-23-2022
By GuruFocusNews GuruFocusNews • 06-10-2022
By Tiesvg Tiesvg • 12-21-2022
By PRNewswire PRNewswire • 12-22-2022
By Value_Insider Value_Insider • 10-19-2022
By GuruFocusNews GuruFocusNews • 02-02-2022
By Business Wire Business Wire • 12-21-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.